---
document_datetime: 2025-05-02 16:37:02
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/capecitabine-medac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: capecitabine-medac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.8200558
conversion_datetime: 2025-12-25 02:12:43.663841
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Capecitabine medac

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                  |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/531/2 02404    | Periodic Safety Update EU Single assessment - capecitabine                                                                                            | 30/01/2025                          | 28/03/2025                                  | SmPC                             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/531/202404. |
| IA/0032              | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate | 05/04/2024                          | n/a                                         |                                  |                                                                                                                                          |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IB/0031/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.a.3.b.6 - Changes in the composition (excipients) of the finished product - Other excipients - Replacement of a single excipient with a comparable excipient with the same functional characteristics and at a similar level B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold | 30/03/2023 | 29/02/2024 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0030/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition) B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition) | 01/02/2023 | n/a |

<div style=\"page-break-after: always\"></div>

| IA/0029           | B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form                                                                                                                                      | 25/04/2022   | 04/04/2023   | SmPC, Labelling and PL   |                                                                                          |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------------------------------------------------------------------------|
| PSUSA/531/2 02104 | Periodic Safety Update EU Single assessment - capecitabine                                                                                                                                                                                                                                                                                                             | 02/12/2021   | n/a          |                          | PRAC Recommendation - maintenance                                                        |
| IB/0028           | C.I.7.b - Deletion of - a strength                                                                                                                                                                                                                                                                                                                                     | 29/10/2021   | 24/03/2022   | SmPC, Labelling and PL   |                                                                                          |
| IAIN/0026         | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                         | 19/02/2021   | 24/03/2022   | SmPC and PL              |                                                                                          |
| IA/0025           | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                            | 25/09/2020   | n/a          |                          |                                                                                          |
| IB/0024/G         | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test | 30/07/2020   | n/a          |                          |                                                                                          |
| A31/0021          | Pursuant to Article 31 of Directive 2001/83/EC, France requested on 13 March 2019 the opinion of                                                                                                                                                                                                                                                                       | 30/04/2020   | 06/07/2020   | SmPC and PL              | Please refer to the assessment report: Capecitabine medac EMEA/H/A-31/1481/C/002568/0021 |

<div style=\"page-break-after: always\"></div>

|                   | the European Medicines Agency to assess the need to take action at EU level regarding the detection of DPD deficient patients (especially through genotyping and/or phenotyping) in patients treated with fluorouracil and related substances (capecitabine, tegafur and flucytosine). The Agency was requested to assess the impact thereof on the benefit-risk balance of fluorouracil and related substances containing products and to give its opinion on whether the marketing authorisation of these products should be maintained, varied, suspended or revoked.   |            |            |                        |                                                                                                                        |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------|
| IB/0023           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                               | 08/05/2020 | 16/07/2020 | SmPC, Labelling and PL |                                                                                                                        |
| IB/0022           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                               | 10/10/2019 | 06/07/2020 | SmPC, Labelling and PL |                                                                                                                        |
| PSUSA/531/2 01804 | Periodic Safety Update EU Single assessment - capecitabine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/01/2019 | 08/04/2019 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                                  | PSUSA/531/201804.                                                                                                                                                                                                                                                                |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0020     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                      | 12/10/2018 | 08/04/2019 | SmPC                             |                                                                                                                                                                                                                                                                                  |
| IB/0018/G   | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer | 04/04/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                  |
| R/0017      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                           | 21/04/2017 | 16/06/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Capecitabine medac in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0016/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a                                                                                                                     | 01/12/2016 | 16/06/2017 | Annex II and PL                  |                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|             | site for the FP - Secondary packaging - Change to importer, batch release and quality control testing of the FP - batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        | manufacturing site B.II.b.2.c.2 arrangements Including   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------|
| IB/0015     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21/09/2016 | 16/06/2017 | SmPC, Labelling and PL |                                                          |
| IAIN/0014/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the | 21/07/2016 | n/a        |                        |                                                          |

<div style=\"page-break-after: always\"></div>

|                   | relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS   |            |            |             |                                   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IB/0013           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH         | 19/02/2016 | 26/05/2016 | SmPC and PL |                                   |
| PSUSA/531/2 01504 | Periodic Safety Update EU Single assessment - capecitabine                                                                                                                                                                                                           | 03/12/2015 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0011           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH         | 27/05/2015 | 26/05/2016 | SmPC and PL |                                   |
| IAIN/0010         | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                      | 28/04/2015 | n/a        |             |                                   |
| PSUSA/531/2 01404 | Periodic Safety Update EU Single assessment - capecitabine                                                                                                                                                                                                           | 04/12/2014 | n/a        |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0008/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/06/2014   | 09/04/2015   | Annex II and PL   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|
| IB/0007/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a | 03/04/2014   | 09/04/2015   | SmPC and PL       |

<div style=\"page-break-after: always\"></div>

|             | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                        | generic/hybrid/biosimilar   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------|
| IAIN/0006   | A.1 - Administrative change - Change in the name address of the MAH                                                                                                                                                                                                                                                                                                                                                          | 20/11/2013 | 28/02/2014 | SmPC, Labelling and PL | and/or                      |
| IAIN/0005/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                             | 03/10/2013 | n/a        |                        |                             |
| IB/0003     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                 | 26/09/2013 | 28/02/2014 | SmPC and PL            |                             |

<div style=\"page-break-after: always\"></div>

| IB/0004   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 06/09/2013   | 28/02/2014   | SmPC                  |      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|------|
| IB/0002/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch | 18/07/2013   | n/a          |                       | size |
| IB/0001   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                        | 06/03/2013   | 28/02/2014   | SmPC, Annex II and PL |      |